Ambler, PA, United States of America

Xiefan Lin-Schmidt

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 9.5

ph-index = 2

Forward Citations = 14(Granted Patents)


Location History:

  • San Diego, CA (US) (2018 - 2019)
  • Ambler, PA (US) (2019 - 2021)
  • Spring House, PA (US) (2018 - 2023)

Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Xiefan Lin-Schmidt: Innovator in Fusion Protein Technology

Introduction

Xiefan Lin-Schmidt is a prominent inventor based in Ambler, PA (US), known for his significant contributions to the field of biotechnology. He holds a total of 9 patents, showcasing his innovative approach to addressing complex health issues.

Latest Patents

Among his latest patents are the Glucagon-like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and their various applications. These patents detail methods for using GLP1-GDF15 fusion proteins to reduce food intake and to prevent, treat, or ameliorate diseases such as obesity, type 2 diabetes, metabolic syndrome, insulin resistance, and dyslipidemia. The fusion proteins consist of a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

Career Highlights

Xiefan Lin-Schmidt has worked with notable companies in the biotechnology sector, including Janssen Biotech, Inc. and Janssen Sciences Ireland Unlimited Company. His work has significantly impacted the development of therapeutic solutions in the field of metabolic disorders.

Collaborations

He has collaborated with esteemed colleagues such as Chichi Huang and Judith Ann Connor, contributing to the advancement of research and innovation in his field.

Conclusion

Xiefan Lin-Schmidt's work in fusion protein technology exemplifies the potential of innovative solutions to address pressing health challenges. His contributions continue to influence the biotechnology landscape and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…